Phase 2 N=205 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Blepharitis
Primary: Change From Baseline in Ocular Discomfort — -4.1; -2.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 DHA For The Treatment of Pediatric Concussion Related to Sports Injury
Concussion · Mild Traumatic Brain Injury
Primary: Safety of Higher Dosage of DHA — 0; 1 Participants
Phase 2 N=41 To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
Basal Cell Nevus Syndrome · Gorlin Syndrome
Primary: Number of New Surgically Eligible Basal-cell Carcinomas — 34; 2 events per patient year
Phase 2 N=30 Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash
Mucositis
Primary: Change in Pain Scores — 2 score on a scale
Phase 2 N=220 Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
Postoperative Nausea and Vomiting
Primary: Percentage of Participants With Complete Control — 25.0; 18.0 percentage of participants — p=0.4010
Phase 3 N=246 2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
Inflammation and Pain Associated With Cataract Surgery
Primary: Number of Participants With Anterior Chamber Cell Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population…
Phase 2 N=37 Phase II Maraviroc for GVHD Prevention
Hematologic Malignancy
Primary: Day +180 Rate of Grade II-IV Acute GVHD — 22 Participants
Phase 2 N=124 A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
Breast Neoplasms
Primary: Progression Free Survival (PFS) — 6.18; 4.93 Months — p=0.0372
Phase 2 N=39 Candin Safety & Efficacy Study for the Treatment of Warts
Warts · Human Papilloma Virus
Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants
N/A N=85 Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
Gulf War Illness · Insomnia
Primary: Gulf War Illness Symptom Severity Index — 67; 67; 61; 49 score on a scale — p=<0.01
Phase 1 N=100 Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
Safety Issues
Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale
N/A N=10 Pre-Surgical Intervention for Targeted Therapies for Breast Cancer
Invasive Breast Cancer
Primary: Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery — 10 participants
N/A N=168 A Prospective, Multi-Center Evaluation of the ECHELON CIRCULAR Powered Stapler in Left-Sided Colorectal Anastomoses
Left-sided Colon Resection
Primary: Percentage of Participants With Stapler Performance Issues — 11.9 Percentage of subjects
N/A N=140 Retail Outlet Health Kiosk Hypertension Trial
Hypertension
Primary: Total Number of Participants With Blood Pressure Control at 12 Months — 13; 7 Participants
N/A N=180 Weight Change in PWS Over Six Months
Weight Change, Body
Primary: Percent of Change in Weight — 2.35 Percent of change in weight